Cardiac amyloidosis has been underdiagnosed for decades. The echo findings are subtle enough that even experienced sonographers can miss it — and by the time it's diagnosed, the treatment window has often closed. Thankfully, ATTR-targeted therapies have changed that calculus, and identifying the right patients early enough now carries real clinical weight.
In this session, Dr. Neel Patel and us2.ai detail the echocardiographic findings that should put amyloid on your differential. You'll learn how to recognize when further evaluation is warranted, and how AI can be used alongside echo to identify amyloid that may otherwise go unrecognized.
